994 / 1851
Conclusions
No significant differences
were seen in efficacy between
Cisplatin-Etoposide (CE) and Carboplatin-Paclitaxel (CP)
There was no difference in pneumonitis or esophagitis rates
between CE and CP. However,
hematologic toxicities
and N/V were significantly higher in the CE arm
Both
CE and CP with XRT are acceptable standards
of care
to treat stage III NSCLC, and prospective data is
needed to determine the optimum regimen